114 related articles for article (PubMed ID: 21490682)
1. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.
Leja J; Yu D; Nilsson B; Gedda L; Zieba A; Hakkarainen T; Åkerström G; Öberg K; Giandomenico V; Essand M
Gene Ther; 2011 Nov; 18(11):1052-62. PubMed ID: 21490682
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus based on serotype 3.
Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
[TBL] [Abstract][Full Text] [Related]
3. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.
Kawakami Y; Li H; Lam JT; Krasnykh V; Curiel DT; Blackwell JL
Cancer Res; 2003 Mar; 63(6):1262-9. PubMed ID: 12649186
[TBL] [Abstract][Full Text] [Related]
4. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
Toivonen R; Suominen E; Grenman R; Savontaus M
Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
[TBL] [Abstract][Full Text] [Related]
5. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.
Uusi-Kerttula H; Davies J; Coughlan L; Hulin-Curtis S; Jones R; Hanna L; Chester JD; Parker AL
Oncotarget; 2016 May; 7(19):27926-37. PubMed ID: 27056886
[TBL] [Abstract][Full Text] [Related]
6. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.
Stepanenko AA; Chekhonin VP
Virus Res; 2018 Sep; 257():40-51. PubMed ID: 30125593
[TBL] [Abstract][Full Text] [Related]
7. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
8. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
Leja J; Dzojic H; Gustafson E; Oberg K; Giandomenico V; Essand M
Clin Cancer Res; 2007 Apr; 13(8):2455-62. PubMed ID: 17438105
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.
Yu D; Jin C; Leja J; Majdalani N; Nilsson B; Eriksson F; Essand M
J Virol; 2011 Dec; 85(24):13114-23. PubMed ID: 21957304
[TBL] [Abstract][Full Text] [Related]
10. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
11. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
[TBL] [Abstract][Full Text] [Related]
12. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.
Shayakhmetov DM; Li ZY; Ni S; Lieber A
Cancer Res; 2002 Feb; 62(4):1063-8. PubMed ID: 11861383
[TBL] [Abstract][Full Text] [Related]
13. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
15. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.
Wunder T; Schmid K; Wicklein D; Groitl P; Dobner T; Lange T; Anders M; Schumacher U
Cancer Gene Ther; 2013 Jan; 20(1):25-32. PubMed ID: 23196273
[TBL] [Abstract][Full Text] [Related]
16. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer.
Li D; Duan L; Freimuth P; O'Malley BW
Clin Cancer Res; 1999 Dec; 5(12):4175-81. PubMed ID: 10632357
[TBL] [Abstract][Full Text] [Related]
17. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
[TBL] [Abstract][Full Text] [Related]
18. Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions.
van Zeeburg HJ; Huizenga A; Brink A; van den Doel PB; Zhu ZB; McCormick F; Brakenhoff RH; van Beusechem VW
Gene Ther; 2010 Dec; 17(12):1517-24. PubMed ID: 20686507
[TBL] [Abstract][Full Text] [Related]
19. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
Kanerva A; Wang M; Bauerschmitz GJ; Lam JT; Desmond RA; Bhoola SM; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
Mol Ther; 2002 Jun; 5(6):695-704. PubMed ID: 12027553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
